My Best Weight

04/04/2026

“Maybe it’s not smugness… maybe it’s relief.

No longer stuck in a struggle we’ve come to expect.

When obesity is treated, the constant mental load can ease — and people often feel more at ease.

That can look like confidence.
It can feel unfamiliar to others.

But improving health and quality of life is the point.

What do you think?

Thanks for letting me give my perspective on this Confession

01/04/2026

💊 Orforglipron (Foundayo)- approved by the FDA in the US: the first oral, non-peptide GLP-1 for obesity

NOT YET APPROVED OR AVAILABLE IN EU/IRELAND

A once-daily tablet designed to deliver clinically meaningful weight loss and metabolic benefit — without injections.

⸻

🧠 What is it?
• Oral GLP-1 receptor agonist
• No fasting requirements (vs oral semaglutide)
• Stepwise dose escalation (0.8 mg to 17.2 mg daily)
• For obesity ± type 2 diabetes

⸻

📊 What do the trials show? (ATTAIN)
• ~10–12% average weight loss (up to ~12.4%)
• ~60% achieve ≥10% body weight change
• ~40% achieve ≥15% body weight change

• HbA1c ↓ ~1.3–1.8% (T2D)
• Effective for weight maintenance after injectables

⸻

⚖️ Tolerability
• GLP-1 class profile - mostly GI issues
• Nausea, diarrhoea, vomiting, constipation
• ~5–10% discontinue (dose-dependent)
• No clear side effect advantage vs injectables
• Gradual escalation is key

⸻

🧩 Where does it fit?
• A lower-barrier entry to evidence-based treatment
• Option for those who don’t want injections
• Useful for earlier intervention or maintenance
• Less potent than tirzepatide — but clinically meaningful

⸻

🧭 Bottom line
This is about access and scalability — not a shortcut.
Obesity remains a chronic disease, and treatment still requires structure, support, and follow-up.

⸻

💬 Would you consider a tablet over an injection?

27/03/2026

“If the scale didn’t exist… how would you know your treatment was effective?”

I ask people to complete a detailed health questionnaire before their first visit, it’s not just about numbers - it’s about understanding impact on health, wellbeing and quality of life!

Response in obesity care isn’t defined by weight loss alone.

We care about:
• Real improvements in your health that you can feel, not just measure
• Moving more freely, with energy to engage fully in your life
• Living your life with freedom, not constantly thinking about weight & dieting
• Greater confidence in your long-term health and wellbeing.

This is about health. Function. Quality of life.
Not just weight.

👇 Tell me — how would you define response without using numbers or weight?

13/03/2026

Semaglutide & Vision 👀 Risk - what does the evidence actually show?

👁 NAION (non-arteritic anterior ischaemic optic neuropathy) is a rare condition caused by reduced blood flow to the optic nerve.

📊 It affects about 2–10 people per 100,000 each year (roughly 1 in 10,000–50,000 people).

Risk is already higher in people with:
- diabetes
- high blood pressure
- sleep apnoea
- cardiovascular disease
- smoking history
- certain optic nerve anatomy

🧾 A new study in the British Journal of Ophthalmology analysed 30+ million adverse-event reports submitted to the US FDA.

The researchers found NAION reports appeared more often in people taking semaglutide medicines. But this does NOT mean the true risk is 17× higher.

Pharmacovigilance databases:
• rely on voluntary reports
• can be influenced by reporting bias and media attention
• cannot calculate the true incidence
• cannot fully adjust for underlying health risks

They are useful because they can detect early safety signals for rare events.

Other studies have shown mixed results.

Some suggest a small relative increase, but the absolute risk remains very low.

Regulators estimate the possible medication-related risk at around 1 in 10,000 people.

➡️ Key takeaway
There is enough emerging evidence to raise awareness and continue monitoring.
But there is not enough evidence to conclude that semaglutide directly causes NAION.
As always, treatment decisions should balance potential risks with the well-established benefits of treating obesity and metabolic disease.

🔗 Study discussed: https://bjo.bmj.com/content/early/2026/03/02/bjo-2025-328483

02/03/2026

28/02/2026

Obesity & treatment options are still being misunderstood in Ireland - and that's exactly why conversations like this matter.

I joined the 2 Johnnie’s on their podcast to talk openly about obesity, weight-loss medications, myths, stigma, and what the science actually tells us. These are conversations we need to be having publicly, not just in clinics.

• Listen to The 2 Johnnie's Podcast Episode 417
"Weight Loss Jabs" here:
https://open.spotify.com/episode/ 1Yb6lXcqYONUEdEVCHOonK?si=l-
RSBvFIRs-4yW9rypdeqw&t=0&pi=6Am0uXrlQpu7M

Thanks to The 2 Johnnies for creating space for an honest discussion.

11/02/2026

Great to have such an open & honest discussion about obesity & treatment options (benefits, response, side effects/ risks). Fair play to The 2 Johnnies for not avoiding a discussion about weight stigma and the judgement people face treating obesity compared to other chronic diseases!

10/02/2026

UPDATE!!
We are excited to see the registrations come in.
We have had enquiries from outside the support groups and are now allocating 10 places for any Healthcare Providers who would like to join us next Thursday.
You MUST register.
See below.

We are delighted to share that registration is open for our in person World Obesity Day Stigma Awareness evening on February 26th in Blanchardstown, Dublin.
We are co-hosting this event with the Association for the Studies of Obesity Ireland (ASOI) and with the support of the European Coalition for People Living with Obesity (ECPO).

This night is open for those who live with overweight or obesity, or affected by obesity, and want to understand more about weight stigma and its consequences.
We hope that family members, friends and colleagues will join too.
If you are a healthcare professional working with patients who may benefit from this evening, please share these details forward!

Soup/sandwiches and Tea/Coffee on arrival at 6.30pm. Kick off 7.00pm

This event is free to join but you MUST register here: https://www.surveymonkey.com/r/StigmaAwarenessWOD2026




ECPObesity

09/02/2026

Our risk of living with excess weight & Obesity is influenced by our genetics, biology (especially subconscious brain), environment and life experiences.
Once our weight is elevated, our body is evolved to defend this higher "set point" to (long term) prevent weight loss and encourage weight regain - this is not failure, lack of willpower or motivation. It is a complex biological issue.
Thanks for welcoming me down to have these chats The 2 Johnnies

09/02/2026

Our obesity expert, Dr Mick Crotty, was absolutely delighted to have such a genuine & insightful discussion about excess weight/obesity with The 2 Johnnies - hopefully this information will help people understand why it's more than just willpower/motivation & reduce weight bias.

Some are branding them as the ‘easy option’, while others have called them a ‘game
changer’! We’re diving into the world of Weight Loss jabs on podcast episode 417! Out now on Spotify.

30/11/2025

A busy weekend for our Obesity Expert, Prof Carel le Roux, as he delivering an engaging lecture entitled "Obesity Management in 2040" to a meeting of international obesity specialist in London.

At My Best Weight we are leading the way on the cutting edge of evidence based obesity care!